Watchdog Demands Answers from FDA on Slow Rolling of Monoclonal Antibodies Treatments for COVID

For Immediate Release

Contact: Kara Zupkus, 224-456-0257

WASHINGTON, D.C. – Today, the Taxpayers Protection Alliance Foundation submitted a Freedom of Information Act (FOIA) request to the Food and Drug Administration (FDA), demanding records from the overbloated agency regarding the slow approval of monoclonal antibodies (mAbs) treatments for the COVID-19 virus.

Although mAbs is an alternative for unvaccinated patients and immunocompromised patients who cannot take the COVID vaccine due to interaction with their existing medications, the FDA bureaucracy appears to be dragging its feet on granting long-term use for mAbs in treating the virus.

TPAF is requesting email communications from FDA Director Dr. Robert Califf and FDA Center for Drug Evaluation and Research Director Dr. Patrizia Cavazzoni regarding the treatment, in an attempt to uncover the truth behind their approval process.

“Americans deserve answers on why the FDA has taken such a lackadaisical approach to approving these potentially life-saving treatments,” TPAF President David Williams said. “We will continue working to hold these unelected government bureaucrats accountable for standing in the way of innovative technologies and treatments that could prove fruitful even beyond COVID, for many chronic diseases. Lifesaving treatments for COVID and future viruses may be at risk if the FDA doesn’t get their act together.  We hope this FOIA brings some sunlight into the dark and non-transparent process at the FDA.”